Accéder au contenu
Merck
Toutes les photos(1)

Documents

C4542

Sigma-Aldrich

Cyclobenzaprine hydrochloride

Synonyme(s) :

5-(3-Dimethylaminopropylidene)dibenzo[a,e]cycloheptatriene hydrochloride

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C20H21N · HCl
Numéro CAS:
Poids moléculaire :
311.85
Numéro CE :
Numéro MDL:
Code UNSPSC :
12352200
ID de substance PubChem :
Nomenclature NACRES :
NA.77

Forme

powder

Niveau de qualité

Auteur

Johnson & Johnson

Chaîne SMILES 

Cl.CN(C)CC\C=C1\c2ccccc2C=Cc3ccccc13

InChI

1S/C20H21N.ClH/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20;/h3-6,8-14H,7,15H2,1-2H3;1H

Clé InChI

VXEAYBOGHINOKW-UHFFFAOYSA-N

Informations sur le gène

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Cyclobenzaprine is a tricyclic agent, which has anti-depressant and anti-cholinergic properties. It lowers the tonic somatic motor activity of motor neuron systems. Cyclobenzaprine prevents the uptake of noradrenaline. It is used to treat neck, back and myofascial pain. Cyclobenzaprine functions as a nerve impulse inhibitor.

Application

Cyclobenzaprine hydrochloride has been used to study its effect on the muscles of dystrophin-deficient mdx5Cv mice.
Cyclobenzaprine hydrochloride has been used to study its effects on the muscles of dystrophin-deficient mdx5Cv mice.

Actions biochimiques/physiologiques

Cyclobenzaprine hydrochloride is a type of tricyclic skeletal drug, which is commonly used as a muscle relaxant. It is very effective in treating intractable pain of cervical and lumbar origin caused by skeletal muscle spasm. cyclobenzaprine hydrochloride inhibit tonic α-mononeuronal excitation mediated by descending serotonergic systems by interacting with serotonin receptors at the spinal cord level.
Skeletal muscle relaxant; reduces muscle spasm by depression of brainstem neurons; 5-HT2 serotonin receptor antagonist.

Caractéristiques et avantages

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogrammes

Skull and crossbones

Mention d'avertissement

Danger

Mentions de danger

Classification des risques

Acute Tox. 3 Oral - Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Faceshields, Gloves


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 1

1 of 1

H Kobayashi et al.
European journal of pharmacology, 311(1), 29-35 (1996-09-05)
The centrally acting muscle relaxant cyclobenzaprine was thought to be an alpha 2-adrenoceptor agonist that reduced muscle tone by decreasing the activity of descending noradrenergic neurons. In the present study, we examined the effects of cyclobenzaprine on descending neurons by
Psychiatric Side Effects of Prescription and Over-the-counter Medications: Recognition and Management (1998)
A validated inherent stability indicating HPTLC method for estimation of cyclobenzaprine hydrochloride in tablets and use of MS-QTOF in characterization of its alkaline stress degradation product
Harde MT, et al.
Bulletin of Faculty of Pharmacy, Cairo University , 54(2), 145-156 (2016)
Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: results of two placebo-controlled trials
Borenstein DG and Korn S
Clinical Therapeutics, 25(4), 1056-1073 (2003)
Determination of degradation products of Cyclobenzaprine hydrochloride, Lidocaine and Piroxicam in a semi-topical formulation: MS-MS confirmation of unknown impurities
Cioroiu BI, et al.
Journal of Chromatographic Science, 54(6), 902-911 (2016)

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique